BlueRock Therapeutics, an engineered cell therapy company, has expanded its ongoing strategic collaboration with the McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto. 
 
BlueRock will be moving into an additional 14,000 square feet within UHN in Toronto’s MaRS Discovery District, co-located with the McEwen Institute. The new lab will be in close proximity to the already established 7,000 square foot faculty housing BlueRock process development and manufacturing teams as well as the new pilot GMP facility, which will open in early 2019. 
 
The expanded partnership will also provide funding to support a BlueRock-endowed research chair in regenerative medicine for Dr. Stephanie Protze, Ph.D., principal investigator, McEwen Stem Cell Institute. A post-doctoral fellow in Dr. Gordon Keller’s lab, Dr. Protze successfully transformed human stem cells into functional pacemaker cardiac cells; these cells were able to elicit a rodent’s heartbeat.
 
“Toronto is an incredible scientific ecosystem and a world-renowned center for stem cell biology and regenerative medicine,” said Emile Nuwaysir, Ph.D., chief executive officer of BlueRock Therapeutics. “The McEwen Stem Cell Institute at UHN is the epicenter of that ecosystem, and we have been very pleased with our relationship to date. The expansion of that partnership deepens the relationship, broadens our access to that foundational science and accelerates the development of our therapeutic programs.”
 
“The collaboration between BlueRock and the McEwen Institute at UHN will continue to greatly enrich and expedite the development of regenerative therapy approaches for cardiovascular disease,” said Dr. Protze. “I am thrilled to have the opportunity to develop BlueRock’s unique Cell+Gene therapy platform and translate its capabilities to new treatments.”